Patent 12168036
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Active provider: Google · gemini-2.5-pro
PTAB activity (2)
AIA trial proceedings — IPR, PGR, CBM — filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced directly from the PTAB Trial API.
- PGR2026-00039PGRfiled Apr 2, 2026vs. Biocon Biologics Limited et al.Pending
- PGR2025-00085PGRfiled Sep 17, 2025vs. Alvotech USA Inc. et al.Trial Instituted
Cached for 24 hours. Status strings are sourced verbatim from the PTAB API; the colored badge is our heuristic classification.
Cases on file (2)
Group view →Specific litigation cases in our database that name US patent 12168036. The free-form analysis below may also discuss cases beyond this list.
- Biocon Biologics, Inc. et al. v. Regeneron Pharmaceuticals, Inc.filed Apr 2, 2026PGR2026-00039Patent Trial and Appeal Board (PTAB)Pending
Defendants: Regeneron Pharmaceuticals, Inc.
- PGR2025-00085Patent Trial and Appeal Board (PTAB)Pending - Instituted
Defendants: Regeneron Pharmaceuticals, Inc.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Post-Grant Review Proceedings Initiated Against U.S. Patent 12,168,036
As of the current date, U.S. Patent 12,168,036 is involved in Post-Grant Review (PGR) proceedings before the Patent Trial and Appeal Board (PTAB). A PGR is a trial proceeding conducted at the PTAB to review the patentability of one or more claims in a patent on any ground that could be raised under § 282(b)(2) or (3).
Details of the known PGR case are as follows:
- Petitioner: Alvotech
- Respondent/Patent Owner: Regeneron Pharmaceuticals, Inc.
- Jurisdiction: Patent Trial and Appeal Board (PTAB)
- Case Number: PGR2025-00085
- Filing Date: The petition was filed and is currently pending. The patent text indicates the case was pending and had been instituted.
- Status: Pending - Instituted. This means the PTAB has found that the petitioner has met the threshold to proceed with the review.
Additionally, a subsequent petition for PGR was filed by Biocon Biologics, Inc. and Biocon Biologics Limited, seeking to join the instituted Alvotech PGR.
- Petitioner: Biocon Biologics, Inc. and Biocon Biologics Limited
- Respondent/Patent Owner: Regeneron Pharmaceuticals, Inc.
- Jurisdiction: Patent Trial and Appeal Board (PTAB)
- Case Number: PGR2026-00039
- Filing Date: April 2, 2026
- Status: The petition seeks joinder with PGR2025-00085 and is substantively identical to Alvotech's petition. The current status of this joinder request is pending.
No other district court or appellate litigation specifically involving U.S. Patent 12,168,036 has been identified at this time. It is important to note that Regeneron has been actively involved in litigation concerning other patents related to its EYLEA® (aflibercept) product against various biosimilar manufacturers, including Mylan, Samsung, and Amgen. These cases, however, do not name U.S. Patent 12,168,036.
Generated 4/30/2026, 8:36:17 PM